Luo et al. found that ANLN could serve as an immune prediction biomarker in lung adenocarcinoma, and there were significant differences in PD-L1 expression levels between the high- and low-CRS subgroups [40]. This evidence concerns the gene ANLN and congenital rubella syndrome.